A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans.

Dermatofibrosarcoma protuberans (DFSP) is a soft-tissue sarcoma characterized by a high risk of local infiltration. The identification of the COL1A1-PDGFB t(17;22) translocation activating the PDGF pathway led to the use of imatinib in unresectable DFSP, with a response rate of 36-80%. Pazopanib is a multitarget tyrosine kinase inhibitor approved for soft-tissue sarcomas.

Association Between Anxiety and New Organ Failure, Independently of Critical Illness Severity and Respiratory Status: A Prospective Multicentric Cohort Study.

Objectives: Anxiety results from the anticipation of a threat and might be associated with poor outcome in the critically ill. This study aims at showing that anxiety at admission in critically ill patients is associated with new organ failure over the first 7 days of ICU hospitalization independently of baseline organ failure at admission.

Design: Prospective multicenter cohort study.

Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry.

Objectives: Rheumatoid arthritis (RA) is responsible for excess mortality mainly due to cardiovascular disease. Studies have found elevated cholesterol levels in RA patients who received tocilizumab (TCZ). We studied the occurrence of major cardiovascular events in RA patients who received TCZ in current practice.

Behaviour of plasma citrulline after bariatric surgery in the BARIASPERM cohort.

Background: Plasma citrulline is currently used in clinical practice as a marker of small bowel functional mass. Behaviour of plasma citrulline after bariatric surgery and its link with post-operative outcome are still poorly understood.

Objective: Primary objective was to compare plasma citrulline 12 months after two types of bariatric surgery with pre-operative concentrations.

Priorities to improve the care for chronic conditions and multimorbidity: a survey of patients and stakeholders nested within the ComPaRe e-cohort.

Objective: To set priorities to improve consultations, care structures and the healthcare system from the perspective of patients with chronic conditions, care professionals, hospital administrators and health policy makers.

Methods: Adult patients with chronic conditions recruited from the ComPaRe e-cohort in France ranked their 15 most important areas of improvement among 147 previously defined by patients. Priorities at a population level were obtained by using logit models for sets of ranked items in a data set calibrated to represent the French population of patients with chronic conditions.

COVID-19-related perceptions, context and attitudes of adults with chronic conditions: Results from a cross-sectional survey nested in the ComPaRe e-cohort.

Background: To avoid a surge of demand on the healthcare system due to the COVID-19 pandemic, we must reduce transmission to individuals with chronic conditions who are at risk of severe illness with COVID-19. We aimed at understanding the perceptions, context and attitudes of individuals with chronic conditions during the COVID-19 pandemic to clarify their potential risk of infection.

Methods: A cross-sectional survey was nested in ComPaRe, an e-cohort of adults with chronic conditions, in France.

Methotrexate and rheumatoid arthritis associated interstitial lung disease.

Question Addressed By The Study: Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA. Whether MTX exposure increases the risk of ILD in patients with RA is disputed.

Development of ARCADIA: a tool for assessing the quality of peer-review reports in biomedical research.

Objective: To develop a tool to assess the quality of peer-review reports in biomedical research.

Methods: We conducted an online survey intended for biomedical editors and authors. The survey aimed to (1) determine if participants endorse the proposed definition of peer-review report quality; (2) identify the most important items to include in the final version of the tool and (3) identify any missing items.

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.

Background: Biannual rituximab infusions over 18 months effectively maintain remission after a "standard" remission induction regimen for patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV).

Objective: To evaluate the efficacy of prolonged rituximab therapy in preventing AAV relapses in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have achieved complete remission after completing an 18-month maintenance regimen.

Design: Randomized controlled trial.

Agreement was moderate between data-based and opinion-based assessments of biases affecting randomized trials within meta-analyses.

Background And Objective: Randomized trials included in meta-analyses are often affected by bias caused by methodological flaws or limitations, but the degree of bias is unknown. Two proposed methods adjust the trial results for bias using empirical evidence from published meta-epidemiological studies or expert opinion.

Methods: We investigated agreement between data-based and opinion-based approaches to assessing bias in each of four domains: sequence generation, allocation concealment, blinding, and incomplete outcome data.

Results of trials assessing transarterial chemoembolization for treating hepatocellular carcinoma are critically underreported.

Objective: We aimed to evaluate to what extent the results of registered randomized controlled trials (RCTs) assessing transarterial chemoembolization (TACE) for treating hepatocellular carcinoma (HCC) are publicly available.

Methods: We searched the Cochrane Central Register of Controlled Trials, the International Clinical Trials Registry Platform, and primary registries for RCTs assessing TACE for treating HCC, registered between January 2008 and August 2018, that had exceeded their completion date by more than 1 year. We systematically searched PubMed, EMBASE, and Google Scholar for a publication as well as the registry for results.

Bayesian analysis from phase III trials was underused and poorly reported: a systematic review.

Objectives: We assessed the reporting of replicability items with the BayesWatch guidelines and crucial items of Bayesian analyses with the Reporting Of Bayes Used in clinical STudies (ROBUST) guidelines in reports of phase III trials.

Study Design And Setting: A literature search of Cochrane CENTRAL, Ovid MEDLINE, and EMBASE database was conducted to identify phase III trials using Bayesian methods for their primary outcome. Two reviewers performed the study selection process independently.

External factors may influence Cochrane reviewers when classifying the risk of bias of original reports.

Objective: The objective of the study was to explore contextual factors associated with high or low risk-of-bias judgment in case of incomplete or unclear information in study reports.

Study Design And Setting: Research-on-research study, using matched case-control design, with a sample of 304 randomized controlled trials (RCTs) included in two Cochrane reviews for which there was disagreement on the risk-of-bias judgment related to incomplete or unclear information in the study report. A case was defined as an RCT judged at high or low risk of bias; a control was the same RCT judged at unclear risk.

Impact of a short version of the CONSORT checklist for peer reviewers to improve the reporting of randomised controlled trials published in biomedical journals: study protocol for a randomised controlled trial.

Introduction: Transparent and accurate reporting is essential for readers to adequately interpret the results of a study. Journals can play a vital role in improving the reporting of published randomised controlled trials (RCTs). We describe an RCT to evaluate our hypothesis that asking peer reviewers to check whether the most important and poorly reported CONsolidated Standards of Reporting Trials (CONSORT) items are adequately reported will result in higher adherence to CONSORT guidelines in published RCTs.

Future of evidence ecosystem series: 3. From an evidence synthesis ecosystem to an evidence ecosystem.

The "one-off" approach of systematic reviews is no longer sustainable; we need to move toward producing "living" evidence syntheses (i.e., comprehensive, based on rigorous methods, and up-to-date).

Future of evidence ecosystem series: 2. current opportunities and need for better tools and methods.

To become user driven and more useful for decision-making, the current evidence synthesis ecosystem requires significant changes (Paper 1. Future of evidence ecosystem series). Reviewers have access to new sources of data (clinical trial registries, protocols, and clinical study reports from regulatory agencies or pharmaceutical companies) for more information on randomized control trials.

Future of evidence ecosystem series: 1. Introduction Evidence synthesis ecosystem needs dramatic change.

Objectives: This article presents why the planning, conduct, and reporting of systematic reviews and meta-analyses of therapeutic interventions are suboptimal.

Study Design And Setting: We present an overview of the limitations of the current system of evidence synthesis for therapeutic interventions.

Results: Systematic reviews and meta-analyses are a cornerstone of health care decisions.

The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence.

Background: Participation in randomized controlled trials (RCTs) may be quite demanding and could represent an important burden for patients. We aimed to explore this research burden (i.e.